Psoriasis future or investigational therapies
|
Psoriasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Psoriasis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Psoriasis future or investigational therapies |
|
Risk calculators and risk factors for Psoriasis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Future or Investigational Therapies
Historically, agents used to treat psoriasis were discovered by experimentation or by accident. In contrast, current novel therapeutic agents are designed from a better understanding of the immune processes involved in psoriasis and by the specific targeting of molecular mediators. Examples can be seen in the use of biologics which target T cells and TNF inhibitors.
It has been suggested that marijuana might treat psoriasis, due to the anti-inflammatory properties of its cannabinoids, and the regulatory effects of THC on the immune system.[1] The adverse effects of marijuana might be overcome by use of more specific cannabinoid receptor medications,[2] to inhibit keratinocyte proliferation.[3]
Future innovation should see the creation of additional drugs that refine the targeting of immune-mediators further.[4]
Research into antisense oligonucleotides carries the potential to provide novel therapeutic strategies for treating psoriasis.[5]
ABT-874 is a human anti-IL-12 monoclonal antibody being developed by Abbott Laboratories in conjunction with Cambridge Antibody Technology for the treatment of multiple autoimmune diseases including psoriasis. Phase II trials have been completed and showed promising results.[6] Abbott is planning to initiate Phase III trials in 2007.[7]
Pseudoceramides
On August 27, 2006, scientists led by Jeung-Hoon Lee created in the laboratory synthetic lipids called pseudoceramides which are involved in skin cell growth and could be used in treating skin diseases such as atopic dermatitis, a form of eczema characterized by red, flaky and very itchy skin; psoriasis, a disease that causes red scaly patches on the skin; and glucocorticoid-induced epidermal atrophy, in which the skin shrinks due to skin cell loss.[8]
References
- ↑ Namazi MR (2005). "Cannabinoids, loratadine and allopurinol as novel additions to the antipsoriatic ammunition". Journal of the European Academy of Dermatology and Venereology : JEADV. 19 (3): 319–22. doi:10.1111/j.1468-3083.2004.01184.x. PMID 15857457.
- ↑ Fowler CJ (2005). "Pharmacological properties and therapeutic possibilities for drugs acting upon endocannabinoid receptors". Current drug targets. CNS and neurological disorders. 4 (6): 685–96. PMID 16375686.
- ↑ Wilkinson JD, Williamson EM (2007). "Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis". J. Dermatol. Sci. 45 (2): 87–92. doi:10.1016/j.jdermsci.2006.10.009. PMID 17157480.
- ↑ Nickoloff BJ, Nestle FO (2004). "Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities". J. Clin. Invest. 113 (12): 1664–75. doi:10.1172/JCI200422147. PMID 15199399.
- ↑ White PJ, Atley LM, Wraight CJ (2004). "Antisense oligonucleotide treatments for psoriasis". Expert opinion on biological therapy. 4 (1): 75–81. doi:10.1517/14712598.4.1.75. PMID 14680470.
- ↑ Heller M. (2007) Positive results for ABT-874 in the treatment of psoriasis J Drugs Dermatol
- ↑ http://www.cambridgeantibody.com/home/products/licensed_products/abbott/abt874
- ↑ Science Daily, New Skin-healing Chemicals